

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Actinogen Medical Limited
ABN	14 086 778 476

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Malcolm McComas
Date of last notice	21 December 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	1. Direct 2. Indirect 3. Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	2. Bunyula Super Pty Ltd <Bunyula Super Fund A/C> - director related entity and contingent beneficial interest 3. McComas Capital Pty Ltd <McComas Family A/C> - controller of trustee & a beneficiary of the trust
Date of change	11 September 2023
No. of securities held prior to change	1. 3,000,000 unlisted options ex @ \$0.10 exp 4/4/2024. 2. 822,223 fully paid ordinary shares. 3. 1,000,000 fully paid ordinary shares issued pursuant to Employee Share Plan.
Class	Fully paid ordinary shares Unlisted options ex @ \$0.0375 exp 11/9/2026
Number acquired	2. 181,107 fully paid ordinary shares 90,554 unlisted options ex @ \$0.0375 exp 11/9/2026 3. 220,265 fully paid ordinary shares 110,133 unlisted options ex @ \$0.0375 exp 11/9/2026
Number disposed	-

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration includes brokerage/gst <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$10,034.30
No. of securities held after change	<ol style="list-style-type: none"> 3,000,000 unlisted options ex @ \$0.10 exp 4/4/2024. 1,003,330 fully paid ordinary shares. 90,554 unlisted options ex @ \$0.0375 exp 11/9/2026. 1,000,000 fully paid ordinary shares issued pursuant to Employee Share Plan. 220,265 fully paid ordinary shares. 110,133 unlisted options ex @ \$0.0375 exp 11/9/2026.
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Take up of entitlements pursuant to rights issue.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.